Viking Therapeutics, Inc. (VKTX)

Viking Therapeutics' leading candidate posted strong mid-stage data and is undergoing phase 3 studies. Though there are some risks, the stock could soar if it can pass the upcoming clinical and regulatory hurdles.

Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro brands.

Novo Nordisk's weight-loss drug CagriSema failed to meet a critical goal in late-stage clinical trials. This shortcoming bodes well for pharmaceutical companies working on similar obesity treatments.

Viking Therapeutics aims to enter the billion-dollar weight loss drug market. The company is studying a candidate in a phase 3 trial.

Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It's a great idea to select tomorrow's potential winners and hold on as their stories unfold.

Viking Therapeutics is nearly done developing and testing a potential GLP-1 weight loss drug. While the company is still losing money, the underlying business appears solid.

Viking should have plenty of news to share with investors this year.

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%.

Viking Therapeutics is aggressively advancing its GLP-1 pipeline, with two pivotal Phase 3 trials now underway or imminent. VKTX's Phase 2 oral data showed up to 14.7% weight loss in 13 weeks, positioning it competitively against current market leaders. With a $3.5B market cap and $706M cash, VKTX trades at a compelling discount to recent sector M&A benchmarks.

/PRNewswire/ -- Equity-Insider.com News Commentary - The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual

Viking Therapeutics is still kept as a speculative buy, with selling pressure subsiding and constructive consolidation signaling renewed investor interest. VKTX's dual-track pipeline and manufacturing agreements position it to rapidly scale commercialization upon regulatory approval, despite a volatile and competitive GLP-1 market. Management's flexible go-to-market strategy and recent commercial leadership appointment highlight readiness to compete independently or via partnership.

Viking Therapeutics posts a wider-than-expected Q4 loss, but shares jump as it advances oral VK2735 into late-stage obesity studies.

Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript

Viking Therapeutics said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year.

Here's a look at the key figures from the quarter.

Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26 Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment VK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26 Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 Million SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided an update on its clinical pipeline and other corporate developments.